The virus
=========

Respiratory syncytial virus (RSV) is a member of the *Pneumovirus* genus, Paramyxovidae family. Its negative-sense single-stranded RNA genome contains 10 genes that encode 11 proteins. Five of these proteins are involved in RNA synthesis: the nucleo-capside N protein, the L protein (polymerase), the phosphoprotein P, and the M2-1 and M2-2 proteins ([@b10-btt-2-433]). Four other RSV proteins are associated with the lipid bilayer to form the viral envelope: the matrix M protein, two glycosylated surface proteins, the F and G proteins, and a small hydrophobic SH protein. The F and G proteins are crucial for the infectivity and pathogenesis of the virus. The G protein mediates attachment of the virus to respiratory epithelial cells, whereas the F (fusion) protein facilitates entry of the virus by fusing viral and cellular membranes and insertion of the RNA into the host cell inducing the formation of the characteristic syncytia ([@b20-btt-2-433]). The F and G proteins carry the antigenic determinants that elicit the production of neutralizing antibodies by the host. The remaining two proteins, NS1 and NS2, are nonstructural accessory proteins involved in modulating the host response to infection. NS1 and NS2 are abundantly present in infected cells and confer virus resistance to type-I interferons enhancing viral replication and survival ([@b42-btt-2-433]). Compared with other close relatives, in RSV the M2-1 protein is essential for the viability of the virus and in its absence transcription terminates nonspecifically and results in expression of NS1 and NS2 alone ([@b13-btt-2-433]).

RSV displays minimal antigenic heterogeneity; however, there are two major RSV subtypes, A and B, which cocirculate each year. Much of the antigenic diversity between and within RSV subtypes is due to variations in the G glycoprotein, with as little as 35% homology between G glycoprotein of strains A and B ([@b24-btt-2-433]). It is not clear whether one subtype is more virulent than the other ([@b12-btt-2-433]; [@b8-btt-2-433]). Antibody responses to the F protein are often cross-reactive for RSV A and B, while antibody responses to the G protein are subtype specific.

Epidemiology
============

RSV is the leading viral pathogen responsible for lower respiratory tract infection (LRTI) requiring hospitalization in infants and young children worldwide. In US alone, it is estimated that at least 140,000 hospitalizations can be attributed to RSV LRTI each year ([@b38-btt-2-433]). The reservoir is exclusively human. RSV outbreaks occur annually and predictably, lasting from late fall through early spring in temperate climates but it can circulate all year long in areas close to the equator ([@b29-btt-2-433]).

The spectrum of RSV disease is wide, ranging from mild upper respiratory tract infection (URI), LRTI, to respiratory failure. Primary RSV infection is almost always symptomatic. Infection with RSV is one of the most common diseases of childhood. It is responsible for 50%--90% of children hospitalized for bronchiolitis and for 5%--40% due to pneumonia ([@b34-btt-2-433]). Approximately two-thirds of infants are infected with RSV during the first year of life, and 90% have been infected one or more times by 2 years of age ([@b17-btt-2-433]). Studies conducted in many different countries over the last 20 years have consistently demonstrated that premature infants and children with chronic lung disease (CLD) and congenital heart disease (CHD) are at greater risk for severe RSV infection. In addition, RSV has been associated with severe respiratory illness in the elderly, immunocompromised patients as well as in previously healthy adults ([@b21-btt-2-433]).

In addition to the acute morbidity, different studies have shown over the past 10 years that young children who had RSV LTRI are at increased risk for developing recurrent wheezing and possibly asthma later in childhood ([@b43-btt-2-433]; [@b39-btt-2-433]).

RSV treatment
=============

While significant advances in the knowledge of RSV biology, immunology, and epidemiology have been made in the last 40 years, there continues to be significant controversy over the optimum management of infants with acute RSV infection.

It has been suggested that RSV viral loads in the respiratory tract correlates with disease severity ([@b26-btt-2-433]; [@b5-btt-2-433]). However, as the disease progresses it is mainly the immune response responsible for the clinical manifestations and the persistence of symptoms ([@b26-btt-2-433]; [@b22-btt-2-433]). Since the initial isolation of the virus, there have been considerable efforts to develop effective therapies for RSV infection: some directed against the virus such as ribavirin, others to modulate the inflammatory response including steroids and anti-leukotrienes, and others to reduce the symptoms such as bronchodilators and heliox or nebulized hypertonic saline ([@b25-btt-2-433]).

To date, however, there is no specific treatment that is uniformly used for the management of this infection in previously healthy infants ([@b36-btt-2-433]). Close monitoring of the clinical evolution and supportive care of patients with intravenous fluids and oxygen remain the mainstay of treatment of RSV disease in the great majority of patients ([@b29-btt-2-433]).

RSV prophylaxis
===============

The lack of effective therapy against RSV infection makes prophylactic interventions the best strategy to avoid the acute and chronic complications of the disease ([@b32-btt-2-433]; [@b40-btt-2-433]). The peak incidence of severe RSV disease is between 2 and 3 months of age. The main risk factors for severe RSV disease in children include prematurity, CLD and CHD. Additional risk factors include male gender, birth during the first half of the RSV season, younger age of RSV acquisition, and malnutrition ([@b33-btt-2-433]). In addition there are several environmental factors that are associated with increased RSV disease severity such as crowding, passive exposure to tobacco smoke, day-care attendance, and the number of older school-age siblings ([@b7-btt-2-433]). Thus, education of parents and other caregivers about methods to decrease the infant's exposure to RSV and to other factors that may contribute to the severity of the infection must form the basis of any RSV prophylaxis program ([@b36-btt-2-433]). Because RSV is transmitted by direct or close contact with contaminated secretions and the virus is known to persist for hours on environmental surfaces and for 30 minutes or longer on hands, emphasis on hand hygiene is crucial ([@b36-btt-2-433]).

Infants affected with RSV shed large quantities of virus in their nasopharyngeal secretions and saliva for up to 3 weeks after the acute episode of RSV LRTI ([@b19-btt-2-433]). High-risk infants and children should not be exposed to individuals with respiratory infections and if at all possible, they should not be in settings (eg, child care centers) where such exposures are likely. Exposure to tobacco smoke must be eliminated since it has been associated with more severe RSV disease. These measures will have the added benefit of decreasing transmission of other respiratory pathogens.

In addition to these hygienic measures, passive immunoprophylaxis of high-risk children initially with a polyclonal RSV Immune Globulin Intravenous (RSV-IGIV; RespiGam™, MedImmune Inc, Gaithersburg, MD, USA) and then with a monoclonal antibody, palivizumab (MEDI-493; Synagis^®^, MedImmune Inc, Gaithersburg, MD, USA), has been shown to reduce hospitalizations due to RSV infections, the surrogate marker for severe RSV lower respiratory tract disease in clinical trials. Despite this success, it is important to remember that most infants with severe RSV disease requiring hospitalization are previously healthy, term infants with no identifiable risk factors.

Passive immunization
--------------------

### Polyclonal antibodies

RSV-IGIV is a hyperimmune polyclonal human intravenous antibody preparation that was prepared from multiple donors. It was licensed by the Food and Drug Administration (FDA) in 1996. Two multicenter, randomized clinical trials demonstrated that monthly RSV-IGIV infusions of 750 mg/kg in children with either prematurity (≤35 weeks of gestation, \<6 months of age) or BPD (age ≤24 months) resulted in a 41%--63% reduction in RSV hospitalization ([@b18-btt-2-433]; [@b35-btt-2-433]). An additional multicenter trial of RSV-IGIV in children \<48 months of age with CHD showed a nonsignficant 31% decrease in RSV hospitalizations. A significant increase in cyanotic episodes and cardiac surgery-related deaths occurred among those children with cyanotic CHD and right to left shunt ([@b41-btt-2-433]). Thus, RSV-IVIG should not be used in children with CHD. Other disadvantages of prophylaxis with RSV-IGIV include the need for intravenous access; the fluid load (15 mL/kg) required to deliver the drug, the potential for transmission of blood-borne pathogens, and the interference with the antibody response to live-virus vaccines. On the other hand, since it is a polyclonal preparation it also offered protection against a variety of pathogens besides RSV. RespiGam, the initially licensed RSV-IVIG preparation, is no longer marketed in the US; its use has been replaced by palivizumab.

Monoclonal antibodies
---------------------

### Palivizumab

Palivizumab is a neutralizing humanized mouse IgG1 mono-clonal antibody directed against one of the two most antigenically stable sites of the F glycoprotein of the virus, site A ([@b3-btt-2-433]). It blocks the fusion of the virus to the host epithelial cell. Palivizumab was completely engineered in the laboratory, and as such 95% is of human origin and only 5% murine. Due to the more conserved nature of these epitopes within the F protein, palivizumab shows a high degree of cross-reactivity among RSV subtypes A and B and is about 50-fold more potent than polyclonal preparations ([@b23-btt-2-433]). It was licensed by the FDA in 1998 ([@b32-btt-2-433]) for prevention of severe RSV disease in preterm infants and children with CLD. More recently, palivizumab was also approved for use in children with hemodynamically significant CHD ([@b14-btt-2-433]). The safety and efficacy of palivizumab in high-risk infants and children was demonstrated in 2 large randomized, placebo-controlled trials.

The IMpact Trial assessed the safety and efficacy of intramuscular palivizumab at a dose of 15 mg/kg provided every 30 days during the RSV season for prevention of RSV hospitalization ([@b32-btt-2-433]). This international, randomized, double blind, placebo-controlled study enrolled 1,502 children who were either were 1) ≤35 weeks of gestation and ≤6 months of age, or 2) ≤24 months of age with CLD that required medical treatment (ie, supplemental oxygen, steroids, bronchodilators, or diuretics) within the previous 6 months at the start of the RSV season. Palivizumab prophylaxis resulted in a 55% overall decrease of RSV-related hospitalization compared to placebo-treated controls. Subgroup analyses by degree of prematurity, and by absence of CLD also yielded significant reductions in RSV hospitalization. Palivizumab prophylaxis also demonstrated clinical efficacy in several secondary endpoints: it reduced the length of hospitalization for RSV infection, decreased requirement for supplemental oxygen, decreased number of days of moderate or severe lower respiratory tract illness, and decreased requirement for hospitalization in the intensive care unit.

Data obtained from the Palivizumab Outcomes Registry, a prospective nationwide registry of 2,116 high-risk children who received palivizumab after its FDA licensure, demonstrated total RSV hospitalization rates of 2.9% compare to the 4.8% reported in the Impact-RSV trial. Thus, the post-licensure real world experience has shown even greater efficacy in reducing hospitalization rates in high-risk children. The majority of the RSV hospitalizations reported to the Registry occurred between the first and second doses, possibly reflecting lower trough concentrations of palivizumab following a single dose ([@b33-btt-2-433])

Palivizumab also has shown benefit in children with CHD. From 1998 to 2002 during 4 consecutive RSV seasons, an international, multicenter, randomized, double blind, placebo-controlled study was conducted. This trial evaluated the safety, tolerance and efficacy of palivizumab for prevention of RSV hospitalization in 1,287 children who were ≤24 months of age with hemodynamically significant CHD ([@b14-btt-2-433]). Eligible children were ≤24 months old and were stratified at entry to a cyanotic or acyanotic group. This study demonstrated that palivizumab was safe in children with cardiac disease and that its use decreased by 45% the rate of RSV hospitalization. Although the trial was not powered to analyze differences among subgroups, hospitalizations were reduced by 29% in those with cyanotic CHD while among those children with acyanotic lesions there was a significant reduction of 58%. In addition, among all study children, there was a 56% decrease in total days of RSV-associated hospitalization per 100 children and a 73% decrease in total RSV-associated hospital days with supplemental oxygen per 100 children. The percentage of children who died was similar in both the palivizumab (3.3%) and placebo (3.7%) groups. None of the fatalities were attributed to the study drug. Palivizumab serum concentrations decreased by 58% after cardiopulmonary bypass, and it is recommended that a postoperative dose of palivizumab be provided in those children who continue to require prophylaxis after such surgery.

The results of this study led to approval of palivizumab by the FDA for prophylaxis in this high-risk group of children. Similarly, the palivizumab Outcomes Registry prospectively collected data on 1,490 subjects with CHD who received RSV prophylaxis with palivizumab from 2000 to 2004. This study demonstrated that total RSV hospitalization rates in those subjects with either cyanotic or acyanotic CHD who received palivizumab were low and decreased from the first to the fourth season (4.3% vs 1.5% respectively) ([@b9-btt-2-433]), confirming the efficacy of palivizumab in this setting.

Palivizumab has not been associated with an increased risk of localized or systemic adverse events. Specifically, there has been no significant difference in hematologic, renal, or hepatic abnormalities between palivizumab and placebo recipients, even with repeated dosing during a second season of prophylaxis. In the IMpact trial, fever, mild injection site erythema, induration or swelling occurred in 3% of recipients. Antibodies to palivizumab have been seen transiently among both drug and placebo recipients, but this has not been associated with adverse reactions. Following licensure of palivizumab, anaphylaxis after re-exposure and acute hypersensitivity reactions on initial and re-exposure to palivizumab have been reported rarely (\<1 in 100,000).

Recommendations for palivizumab prophylaxis
-------------------------------------------

The American Academy of Pediatrics (AAP) has issued a policy statement for the use of palivizumab for prophylaxis of RSV infections in high-risk children ([@b1-btt-2-433]). Palivizumab is administered intramuscularly at a dose of 15 mg/kg monthly (every 30 days) during the RSV season, which typically in the US starts in November and ends in March or April. A maximum of 5 doses is generally sufficient prophylaxis during one season. This recommended dose and schedule assures the maintenance of serum palivizumab concentrations of ≥40 μg/mL, a concentration that has shown to decrease pulmonary RSV replication in the cotton rat model by \>100-fold (Johnson et al 2007). Different studies have shown that protective palivizumab serum through concentrations (\>40 μg/mL) increased after the second dose of 15 mg/kg/month ([@b37-btt-2-433]). Thus, it is important to avoid delaying administration of the second injection dose in order to achieve adequate protective serum levels. High-risk infants and children should receive palivizumab before hospital discharge. Once a child qualifies for prophylaxis, administration should continue throughout the RSV season and not stop at the point he or she reaches any certain age. Since some children experience more than one RSV infection during a given season, infants and children who develop a RSV infection while receiving palivizumab should continue to receive prophylaxis after recovery from their acute infection. Palivizumab can be given with routine immunizations since it does not interfere with the immunologic response to vaccines. Palivizumab is now available in a preservative-free liquid formulation with either 50 mg or 100 mg of palivizumab (Synagis^®^, MedImmune, Inc.) in 0.5 mL or 1 mL vials, respectively ([@b31-btt-2-433]). The liquid form is stable at refrigerator temperatures. The lyophilized form continues to be available. Palivizumab can be given with routine childhood immunizations since it does not interfere with the immunologic response to vaccines. Although RSV mutants resistant to palivizumab have been derived in the laboratory ([@b46-btt-2-433], [@b45-btt-2-433]), no palivizumab-resistant mutants have been described in humans ([@b11-btt-2-433]).

The recommendations issued by the AAP for the use of palivizumab in high-risk children are provided in [Figure 1](#f1-btt-2-433){ref-type="fig"} ([@b1-btt-2-433]). For infants born between 32 weeks, 1 day and 35 weeks, 0 days of gestation, the AAP recommends that prophylaxis be considered only if 2 or more risk factors are present. Although palivizumab has been shown to decrease RSV hospitalization in these infants, and infants 33--35 weeks of gestation may have adverse hospital outcomes secondary to RSV ([@b4-btt-2-433]), the health-care expenditures of prophylaxis makes routine administration of palivizumab problematic in this group of infants.

Children with hemodynamically significant CHD are candidates for prophylaxis. However, the degree of physiologic cardiovascular compromise must be assessed. Children with the following cardiac lesions are not at increased risk for severe RSV infection and generally are not considered candidates for immunoprophylaxis: 1) hemodynamically insignificant CHD such as secundum atrial septal defect, small ventricular septal defect, pulmonic stenosis, uncomplicated aortic stenosis, mild coarctation of the aorta, and patent ductus arteriosus; 2) lesions adequately corrected by surgery unless there is continued requirement of medication for congestive heart failure; and 3) mild cardiomyopathy not requiring medical therapy.

Motavizumab
-----------

Monoclonal antibody variants derived from palivizumab have been generated by modifying antibody binding kinetics that resulted in increased binding avidity and viral neutralization activity ([@b27-btt-2-433]). One of these antibodies, motavizumab (Medi-524 or Numax™), a second-generation mAb, has been shown to decrease lower and upper airway RSV loads in cotton rats by 50- to 110-fold compared with palivizumab.

A recent multinational, randomized double blind, phase III clinical trial assessed the safety and relative efficacy of motavizumab and palivizumab at reducing RSV specific hospitalizations and outpatient medically attended lower respiratory tract infections (LRIs). Over 2 consecutive RSV seasons 6,635 pre-term infants ≤35 weeks gestation and ≤6 months of age or preterm infants ≤24 months of age with CLD requiring treatment were randomized to receive palivizumab (n = 3,3326) or motavizumab (n = 3,329) at 15 mg/kg IM monthly, and followed for 150 days. Administration of either mAb resulted in very low rates of RSV hospitalization (1.4% vs 1.9% for motavizumab vs palivi-zumab respectively). However, motavizumab showed better protection against RSV outpatient medically attended LRIs with a 50% relative reduction in RSV specific LRIs compared with palivizumab (2% vs 3.9%, respectively (p \< 0.01) ([@b6-btt-2-433]). A phase III clinical study is ongoing to evaluate safety and efficacy of motavizumab versus palivizumab at reducing severe RSV disease in patients with hemodinamically significant CHD. Most recently, a third-generation mAb, Numax-YTE, has been generated with the intent to extend the serum half-life of the mAbs in humans. If successfully developed, this drug may offer the opportunity for less frequent dosing, obviating the need for the monthly treatments that are required with palivizumab ([@b30-btt-2-433]).

Prophylaxis in other high-risk populations
------------------------------------------

There are other several high-risk groups that may benefit from prophylaxis; however insufficient data exist to recommend its routine use. In these situations physicians caring for these patients make individualized decisions on the basis of the available data and the unique situation of each patient. Viral respiratory infections, including RSV infections, are commonly associated with acute pulmonary exacerbations in patients with cystic fibrosis (CF) ([@b44-btt-2-433]). The short-term morbidity of RSV infection in young children with CF (length of hospitalization and ICU stay) appears to be comparable to that of children with CLD ([@b2-btt-2-433]). A recent retrospective cohort study in 75 children diagnosed with CF at ≤18 months of age (35 of whom received palivizumab prophylaxis) showed a reduced but not significant length of hospitalization during the first RSV season in patients that received the prophylaxis, suggesting that young children with CF may benefit from the use of palivizumab ([@b16-btt-2-433]). Results are pending of a phase IV multicenter, randomized, double blind, placebo-controlled study on the safety and tolerance of palivizumab in children ≤24 months of age with cystic fibrosis.RSV can cause serious respiratory illness among solid organ transplant (SOT) patients, yet there is no standard recommendation for RSV immunoprophylaxis. To learn the current practices for the prevention of RSV disease in pediatric SOT candidates and recipients in the US, a 24-questionnaire survey was mailed to 108 SOT programs in 2006. The types of SOT programs included: liver, heart, lung, intestine, and heart-lung types of transplants. Among the programs that completed the survey, 49% reported the use of prophylaxis with palivizumab with similar rates among recipients of all organ types. No data on RSV hospitalizations and outcomes were obtained and this information is crucial to develop a more rational approach to RSV immunoprophylaxis in these high-risk patients ([@b15-btt-2-433]).

Potential long-term benefits of anti-RSV prophylaxis
----------------------------------------------------

In addition to reducing the acute morbidity, there also may be potential benefits from prevention of long term RSV sequelae such as recurrent wheezing and asthma. In an animal model of RSV infection, prophylactic administration of both palivizumab and motavizumab significantly reduced the development of airway hyperreactivity and chronic airway inflammation ([@b27-btt-2-433], [@b28-btt-2-433]). In humans, a recent double cohort multicenter study showed that preterm infants who received palivizumab prophylaxis during their first RSV season had a significant lower risk of subsequent recurrent wheezing during a 24-month follow-up compared with age-matched controls who did not receive prophylaxis ([@b40-btt-2-433]). Despite its limitations this is a crucial study that demonstrates for the first time in humans that interventions directed against acute RSV can provide a long-term benefit. Future, prospective, randomized, placebo-controlled studies should be developed to confirm these important findings.
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